Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.

Carducci M, Shaheen M, Markman B, Hurvitz S, Mahadevan D, Kotasek D, Goodman OB Jr, Rasmussen E, Chow V, Juan G, Friberg GR, Gamelin E, Vogl FD, Desai J.

Invest New Drugs. 2018 Dec;36(6):1060-1071. doi: 10.1007/s10637-018-0625-6. Epub 2018 Jul 7.

2.

Opportunities and Challenges in Implementation of Multiparameter Single Cell Analysis Platforms for Clinical Translation.

Keating SM, Taylor DL, Plant AL, Litwack ED, Kuhn P, Greenspan EJ, Hartshorn CM, Sigman CC, Kelloff GJ, Chang DD, Friberg G, Lee JSH, Kuida K.

Clin Transl Sci. 2018 May;11(3):267-276. doi: 10.1111/cts.12536. Epub 2018 Mar 2. Review.

3.

Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL).

Friberg G, Reese D.

Ann Oncol. 2017 Aug 1;28(8):2009-2012. doi: 10.1093/annonc/mdx150. No abstract available.

PMID:
28379283
4.

A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia.

Kantarjian HM, Schuster MW, Jain N, Advani A, Jabbour E, Gamelin E, Rasmussen E, Juan G, Anderson A, Chow VF, Friberg G, Vogl FD, Sekeres MA.

Am J Hematol. 2017 Jul;92(7):660-667. doi: 10.1002/ajh.24736. Epub 2017 Jun 5.

5.

A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction.

Wu B, Lewis LD, Harvey RD, Rasmussen E, Gamelin E, Sun YN, Friberg G, Koyner JL, Dowlati A, Maitland ML.

Clin Pharmacol Ther. 2017 Aug;102(2):313-320. doi: 10.1002/cpt.617. Epub 2017 Jun 9.

PMID:
28074547
6.

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.

Aldoss I, Bargou RC, Nagorsen D, Friberg GR, Baeuerle PA, Forman SJ.

Leukemia. 2017 Apr;31(4):777-787. doi: 10.1038/leu.2016.391. Epub 2016 Dec 28. Review.

PMID:
28028314
7.

A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors.

Dowlati A, Vlahovic G, Natale RB, Rasmussen E, Singh I, Hwang YC, Rossi J, Bass MB, Friberg G, Pickett CA.

Clin Cancer Res. 2016 Sep 15;22(18):4574-84. doi: 10.1158/1078-0432.CCR-15-2145. Epub 2016 Apr 13.

8.

Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.

Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S.

Invest New Drugs. 2015 Jun;33(3):691-9. doi: 10.1007/s10637-015-0236-4. Epub 2015 Apr 21.

PMID:
25895965
9.

Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.

Fleming GF, Schumm P, Friberg G, Ratain MJ, Njiaju UO, Schilsky RL.

BMC Cancer. 2015 Feb 18;15:69. doi: 10.1186/s12885-015-1075-6.

10.

A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.

Hong DS, Kurzrock R, Mulay M, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Rosen LS.

Oncotarget. 2014 Nov 30;5(22):11154-67.

11.

AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.

Juan G, Bush TL, Ma C, Manoukian R, Chung G, Hawkins JM, Zoog S, Kendall R, Radinsky R, Loberg R, Friberg G, Payton M.

J Transl Med. 2014 Nov 4;12:307. doi: 10.1186/s12967-014-0307-x.

12.

A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.

Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelson DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Appleman LJ.

Clin Genitourin Cancer. 2014 Jun;12(3):167-177.e2. doi: 10.1016/j.clgc.2013.11.007. Epub 2013 Nov 13.

13.

AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.

Bush TL, Payton M, Heller S, Chung G, Hanestad K, Rottman JB, Loberg R, Friberg G, Kendall RL, Saffran D, Radinsky R.

Mol Cancer Ther. 2013 Nov;12(11):2356-66. doi: 10.1158/1535-7163.MCT-12-1178. Epub 2013 Aug 29.

14.

Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.

Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, Gilbert J, Mahalingam D, McCaffery I, Michael SA, Mita AC, Mita MM, Mulay M, Shubhakar P, Zhu M, Sarantopoulos J.

Clin Cancer Res. 2012 Jun 15;18(12):3414-27. doi: 10.1158/1078-0432.CCR-11-3369. Epub 2012 Apr 17.

15.

Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.

Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, Benedetto PW, Friberg G, Deng H, McCaffery I, Leitch I, Badola S, Chang S, Zhu M, Tolcher A.

J Clin Oncol. 2012 May 20;30(15):1849-56. doi: 10.1200/JCO.2011.37.2359. Epub 2012 Apr 16.

PMID:
22508822
16.

Characterization of 64Cu-DOTA-conatumumab: a PET tracer for in vivo imaging of death receptor 5.

Rossin R, Kohno T, Hagooly A, Sharp T, Gliniak B, Arroll T, Chen Q, Hewig A, Kaplan-Lefko P, Friberg G, Radinsky R, Evelhoch JL, Welch MJ, Hwang DR.

J Nucl Med. 2011 Jun;52(6):942-9. doi: 10.2967/jnumed.110.086157. Epub 2011 May 13.

17.

Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.

Doi T, Murakami H, Ohtsu A, Fuse N, Yoshino T, Yamamoto N, Boku N, Onozawa Y, Hsu CP, Gorski KS, Friberg G, Kawaguchi T, Sasaki T.

Cancer Chemother Pharmacol. 2011 Sep;68(3):733-41. doi: 10.1007/s00280-010-1544-1. Epub 2010 Dec 16.

PMID:
21161528
18.

A first-in-human study of conatumumab in adult patients with advanced solid tumors.

Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, Friberg G, LoRusso PM.

Clin Cancer Res. 2010 Dec 1;16(23):5883-91. doi: 10.1158/1078-0432.CCR-10-0631. Epub 2010 Oct 14.

19.

Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling.

Zoog SJ, Ma CY, Kaplan-Lefko PJ, Hawkins JM, Moriguchi J, Zhou L, Pan Y, Hsu CP, Friberg G, Herbst R, Hill J, Juan G.

Cytometry A. 2010 Sep;77(9):849-60. doi: 10.1002/cyto.a.20940.

20.

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H, Friberg G, Puzanov I.

J Clin Oncol. 2009 Dec 1;27(34):5800-7. doi: 10.1200/JCO.2009.23.6745. Epub 2009 Sep 28.

PMID:
19786654
21.

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.

Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF; Chicago Phase II Consortium; PMH Phase II Consortium; California Phase II Consortium.

Gynecol Oncol. 2008 Jul;110(1):49-55. doi: 10.1016/j.ygyno.2008.02.009. Epub 2008 Apr 18.

22.

Chemotherapy in endometrial cancer.

Obel JC, Friberg G, Fleming GF.

Clin Adv Hematol Oncol. 2006 Jun;4(6):459-68. Review.

PMID:
16981669
23.

Is oral tegafur with leucovorin equivalent to intravenous 5-fluorouracil and leucovorin in colorectal cancer?

Friberg G, Schilsky RL.

Nat Clin Pract Oncol. 2006 May;3(5):240-1. No abstract available.

PMID:
16682999
24.

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.

Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE.

J Clin Oncol. 2005 Nov 1;23(31):8033-40.

PMID:
16258101
25.

Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer.

Kindler HL, Friberg G, Skoog L, Wade-Oliver K, Vokes EE.

Am J Clin Oncol. 2005 Aug;28(4):340-4.

PMID:
16062074
26.

Chemotherapy for advanced pancreatic cancer: past, present, and future.

Friberg G, Kindler HL.

Curr Oncol Rep. 2005 May;7(3):186-95. Review.

PMID:
15847709
27.

Intraperitoneal chemotherapy for ovarian cancer.

Friberg G, Fleming G.

Curr Oncol Rep. 2003 Nov;5(6):447-53. Review.

PMID:
14521802
28.

A clinical study of competency to consent to treatment in pediatrics.

Billick SB, Burgert W 3rd, Friberg G, Downer AV, Bruni-Solhkhah SM.

J Am Acad Psychiatry Law. 2001;29(3):298-302.

PMID:
11592457
29.

Pantethine inhibits the formation of high-Tc protein aggregates in gamma B crystallin solutions.

Friberg G, Pande J, Ogun O, Benedek GB.

Curr Eye Res. 1996 Dec;15(12):1182-90.

PMID:
9018433

Supplemental Content

Loading ...
Support Center